The German company CureVac said on Friday that its Covid-19 vaccine had passed its first interim analysis, but that it was not yet ready to share data on how well it protects against infection. The company said that an independent Data Safety Monitoring Board found no safety concerns. But the board did not share any efficacy data, suggesting that it’s not yet clear just how much protection the vaccine provides. “The trial will continue to collect sufficient data in order to conduct statistically significant efficacy analysis,” the company said in its statement. The CureVac vaccine is based on mRNA technology, like the ones developed by Moderna and Pfizer-BioNTech.

Source: New York Times May 28, 2021 22:01 UTC